The impact of public coverage of newer hepatitis C medications on utilization, adherence, and costs in British Columbia

Harriet Ho1*, Naveed Z. Janjua2,3,4, Kimberly M. McGrail1, Mark Harrison4,5, The BC Hepatitis Testers Cohort Team2¶, Michael R. Law1

1 The Centre for Health Services and Policy Research, School of Population and Public Health, The University of British Columbia, Vancouver, British Columbia, Canada, 2 British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada, 3 School of Population and Public Health, The University of British Columbia, Vancouver, British Columbia, Canada, 4 Centre for Health Evaluation and Outcomes Sciences, St. Paul’s Hospital, Vancouver, British Columbia, Canada, 5 Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada

¶ Membership of the BC Hepatitis Testers Cohort Team is provided in the Acknowledgments.
* harrietho@alumni.ubc.ca

Abstract

Background

Sofosbuvir and ledipasvir-sofosbuvir are both newer direct-acting antiviral agents for the treatment of hepatitis C. The high list prices for both drugs have led to concern about the budget impact for public drug coverage programs. Therefore, we studied the impact of public prescription drug coverage for both drugs on utilization, adherence, and public and private expenditure in British Columbia, Canada.

Methods

We used provincial administrative claims data from January 2014 to June 2017 for all individuals historically tested for either hepatitis C and/or human immunodeficiency virus. Using interrupted time series analysis, we examined the impact of public insurance coverage on treatment uptake, adherence (proportion of days covered), and public and private expenditure.

Results

Over our study period, 4,462 treatment initiations were eligible for analysis (1,131 sofosbuvir and 3,331 ledipasvir-sofosbuvir, which include 19 patients initiated on both treatments). We found the start of public coverage for sofosbuvir and ledipasvir-sofosbuvir increased treatment uptake by 154%. Adherence rates were consistently high and did not change with public coverage. Finally, public expenditure increased after the policy change, and crowded out some private expenditure.

Conclusion

Public coverage for high-cost drugs for hepatitis C dramatically increased use of these drugs, but did not reduce adherence. From a health policy perspective, public payers should
be prepared for increased treatment uptake following the availability of public coverage. However, they should not be concerned that populations without private insurance coverage will be less adherent and not finish their treatment course.

Introduction

Specialty pharmaceuticals are a designation of drugs that are considered high-cost [1]. Spending on specialty pharmaceuticals is expected to grow in the coming years and is projected to constitute 50 percent of health plans’ overall drug spending by 2019, making them a major issue for both public and private payers [2]. Sofosbuvir (SOF) and ledipasvir/sofosbuvir (LDV/SOF) are two newer specialty drugs that treat hepatitis C virus (HCV) with a high cure rate. The high costs of these therapies have been very controversial, with a once-a-day, eight- to 24-week course of treatment costing, on average, $60,000 per patient [3]. This has led to concern from both public and private insurers about the cost implications given the prevalence of HCV in the population. There has been limited study on the impact of public coverage of direct acting antivirals (DAAs), such as SOF and LDV/SOF, on treatment uptake and expenditure. One study conducted in the US examined found that Medicaid coverage of SOF led to a short-lived increase in prescription volume and expenditures within the program [4]. However, it is unclear what the impact of coverage of SOF had at the population level.

A related consideration is whether broader public coverage, including for at-risk patients, will have implications for adherence to prescriptions. Adherence is crucial to the effectiveness of DAAs to obtain maximum response to treatment, avoid treatment failure, and prevent resistance [5]. With the high cost of SOF and LDV/SOF, ensuring that treatment achieves the best outcomes through high adherence is one way to maximize value for money. To date there has been very little study of patient adherence to new DAAs outside of clinical trials [6–9]. In other drugs, decreased out-of-pocket costs were associated with higher adherence [10, 11]. However, SOF and LDV/SOF have short, defined treatment courses, which may see different effects of coverage on adherence, compared to drugs taken for more extended durations, such as statins, in these prior studies. Further, it is unclear whether adherence behaviours will be different between populations with private coverage and those who received public coverage under the expansion.

In the absence of good data on the outcomes and cost implications of coverage, different insurers have been imposing different clinical criteria on coverage for these medications. For example, British Columbia’s (BC) public PharmaCare program introduced coverage for SOF and LDV/SOF more than a year after the first prescription of SOF was dispensed in BC [12]. This coverage was initially made with strict clinical criteria including fibrosis at stage F2 or higher [3]. As a growing number of new and expensive specialty medicines becomes available, the impact of public listing becomes an important consideration for both public drug plans and employers providing private drug coverage in Canada. To provide insight about the impact of this coverage, we used rigorous longitudinal methods to analyze trends in adherence, treatment uptake, and expenditure for SOF and LDV/SOF following public coverage.

Materials and methods

Study context

This analysis was part of a larger project that was granted ethics approval by the University of British Columbia Research Ethics Board (#: H15-01776). Participant consent was not required because analysis was performed on the de-identified data.
BC’s health care system consists of a single-payer system for physician and hospital services, with a mix of public and private payers for prescription drugs dispensed outside of hospitals [13]. Under PharmaCare, BC residents can enrol in one of several plans, the largest of which is the income-based Fair PharmaCare plan [14]. This plan requires most households to spend a certain proportion of their household income as a deductible before public coverage commences. There are also other plans with more extensive subsidy, such as a plan for recipients of social assistance payments. PharmaCare coverage of SOF and LDV/SOF commenced in March 2015 [12]. Prior to this, these drugs could be accessed by using private insurance plans (where they chose to provide coverage) or out-of-pocket payments by individuals. Of note, even after public listing, private insurance plans could still cover the portion of the drug cost under any applicable public plan deductible or for individuals who do not meet the public plan’s clinical criteria.

Data sources

Our analysis studied the BC Hepatitis Testers Cohort, which is housed at the BC Centre for Disease Control. This cohort includes all individuals in BC who have been tested for HCV or HIV, or reported a case of hepatitis B (HBV), HCV, HIV or active tuberculosis in BC from 1990 to February 2016 [15]. Through personal health numbers, the data are linked to medical visits, hospitalizations, prescription drugs, the cancer registry and mortality data [15].

Healthcare utilization data came from comprehensive sources that capture nearly all BC residents’ health system usage, including diagnoses, medical and surgical procedures, and prescription drug dispensations. Prescription drug data came from PharmaNet, which is a network run by the BC Ministry of Health and the College of Pharmacists of BC [16]. PharmaNet provides comprehensive data on all prescription drugs dispensed through community pharmacies, community health practices, and hospital outpatient pharmacies in BC, regardless of payer [17].

Inclusion criteria

Our analysis examined usage of SOF and LDV/SOF between January 2014 and June 2017. For our analyses of adherence and uptake, we included all initiations prior to January 14, 2017 that had a treatment length not exceeding 168 days to allow adequate time for follow-up of the complete course of treatment.

Statistical analysis

We used interrupted time series (ITS) analysis, which is one of the most robust quasi-experimental study designs that has been used extensively in evaluating drug policy changes [18]. We examined monthly time points; for the adherence and treatment uptake analyses, the monthly time points were the starting month of treatment for a patient. As PharmaCare coverage began on March 23, 2015, we classified March 2015 as being in the pre-period as the majority of the month fell into that time period. Since the effects of the coverage changes may not be immediate, we used a three-month phase-in period in our analyses by excluding the data points for three months following the announcement (April to June 2015).

We examined three key outcome variables in our ITS analyses:

- **Number of individuals treated**—The total number of individuals who started treatment in each month.
- **Adherence**—Proportion of days covered (PDC) measures the percentage of days that medication is available and is capped at 100%. The total number of days evaluated can either be the
treatment duration or a defined study period (e.g., 30 days, 90 days) for a chronic disease treatment. As the recommended durations of treatments are 8, 12, 16, and 24 weeks, we defined treatment periods in the equivalent number of days: 56, 84, 112, or 168 days. We identified treatment courses based on quantity of pills dispensed, rounded up to the next treatment course. Treatment duration is dependent on factors, including genotype of HCV [19]. We examined the average PDC at each month, weighted by the number of individuals in that month.

\[
PDC = \frac{\text{total days supply}}{\text{total number of days evaluated}} \times 100\%
\]

- **Public and private expenditure**—The total amounts of public and private expenditure in each month.

  In all of our analyses, we used generalized least squares (GLS) models with appropriate adjustment for autocorrelation [20]. All analyses were conducted using SAS Version 9.4 and R Version 3.3.2.

**Results**

**Cohort characteristics**

Our cohort contained 4,462 initiations of SOF and LDV/SOF during our study period (Table 1). Among these treatments, 19 individuals were treated twice (once with each treatment); thus, the cohort contained 4,443 unique individuals. The average age was 57.9 years, and 32.3% were female. Of those treated with SOF or LDV/SOF, 93.3% were white, 43.9% belonged to the least privileged category of material deprivation, 4.7% had an injection drug use diagnosis, and 15.5% had cirrhosis.

  While on SOF, patients took an average of 4.46 other drugs, with 14.9% taking interferon, 82.8% taking ribavirin, and 14.9% taking both interferon and ribavirin (Table 2). While on LDV/SOF, patients took fewer other drugs. Patients took an average of 3.05 other drugs, with 0.1% taking interferon, 2% taking ribavirin and, and 0.1% taking both interferon and ribavirin.

**Treatment uptake**

After the institution of public coverage, there was a sustained increase of 189 new individuals treated per month (p < 0.001), followed by a decrease in treatment uptake of 19 individuals per month (p < 0.001) (Table 3 and Fig 1). Over the entire follow-up period, this represented a net increase of just 27 people compared to the counterfactual.

**Adherence**

Adherence rates in the period before public coverage were high, with an average PDC of 95.8% across these 15 months. These levels remained high following the coverage change (Fig 2). Neither the change in level nor trend were significantly different from zero for these drugs, suggesting that PharmaCare coverage did not reduce these high adherence rates.

**Public and private expenditure**

Looking across all use of the study drugs (including both initiations and other users), we found an immediate increase of $21.36 million in average monthly public expenditure (p < 0.001, 95% CI: $19.53 million, $23.18 million), and a decrease of $842,053 per month.
| Variable                                                   | n = 4,443 | %  |
|-----------------------------------------------------------|-----------|----|
| Treatment type                                            |           |    |
| Sofosbuvir<sup>b</sup>                                     | 1,112     | 25.0|
| Ledipasvir-sofosbuvir<sup>b</sup>                           | 3,312     | 74.5|
| Sofosbuvir and ledipasvir-sofosbuvir                       | 19        | 0.4 |
| Sex                                                       |           |    |
| Female                                                    | 1,434     | 32.3|
| Male                                                      | 3,009     | 67.7|
| Age                                                       |           |    |
| < 50                                                      | 695       | 15.6|
| 50–60                                                     | 1,713     | 38.6|
| > 60                                                      | 2,035     | 45.8|
| Ethnicity                                                 |           |    |
| Non-White                                                 | 268       | 6.0 |
| White                                                     | 4,146     | 93.3|
| Unknown                                                   | 29        | 0.7 |
| PharmaCare                                                |           |    |
| No                                                        | 1,081     | 24.3|
| Yes                                                       | 3,362     | 75.7|
| Treatment duration                                        |           |    |
| 56 days                                                   | 908       | 20.4|
| 84 days                                                   | 2,277     | 51.2|
| 112 days                                                  | 73        | 1.6 |
| 168 days                                                  | 1,185     | 26.7|
| Previous treatment                                        |           |    |
| No                                                        | 3,258     | 73.3|
| Yes                                                       | 1,185     | 26.7|
| Material deprivation                                      |           |    |
| Most privileged                                           | 1,501     | 33.8|
| Moderately privileged                                     | 902       | 20.3|
| Least privileged                                          | 1,951     | 43.9|
| Unknown/missing                                           | 89        | 2.0 |
| Elixhauser comorbidity index                               |           |    |
| 0                                                         | 1,479     | 33.3|
| 1                                                         | 986       | 22.2|
| ≥ 2                                                       | 1,978     | 44.5|
| Cirrhosis                                                 |           |    |
| No                                                        | 3,755     | 84.5|
| Yes                                                       | 688       | 15.5|
| Diabetes                                                  |           |    |
| No                                                        | 3,947     | 88.8|
| Yes                                                       | 496       | 11.2|
| Hepatitis B (HBV)                                         |           |    |
| No                                                        | 4,128     | 92.9|
| Yes                                                       | 315       | 7.1 |
| Hepatocellular carcinoma (HCC)                             |           |    |
| No                                                        | 4,387     | 98.7|
| Yes                                                       | 56        | 1.3 |

(Continued)
thereafter ($p < 0.001, 95\% \text{CI}: -$999,267, -$684,839$) (Fig 3). After the policy change, there was a sustained decrease of $3.84 million in average monthly private expenditure ($p < 0.001, 95\% \text{CI}: -$4.53 million, -$3.14 million), followed by a $417,528 decrease per month ($p < 0.001, 95\% \text{CI}: -$470,932, -$364,124$). Overall, this suggests that public coverage crowded out at least a portion of the private payments that would have been expected absent the public listing.

Table 1. (Continued)

| Variable                        | n = 4,443 | %     |
|---------------------------------|-----------|-------|
| Major mental illness            |           |       |
| No                              | 3,065     | 69.0  |
| Yes                             | 1,378     | 31.0  |
| Injection drug use (IDU) diagnosis |           |       |
| No                              | 4,232     | 95.3  |
| Yes                             | 211       | 4.7   |
| Opioid substitution therapy (OST) |           |       |
| No                              | 4,153     | 93.5  |
| Yes                             | 290       | 6.5   |
| Problem alcohol use             |           |       |
| No                              | 3,280     | 73.8  |
| Yes                             | 1,163     | 26.2  |
| HIV                             |           |       |
| No                              | 4,042     | 91.0  |
| Yes                             | 401       | 9.0   |
| Chronic kidney disease (CKD)    |           |       |
| No                              | 4,430     | 99.7  |
| Yes                             | 13        | 0.3   |
| End-stage renal disease (ESRD)  |           |       |
| No                              | 4,435     | 99.8  |
| Yes                             | 8         | 0.2   |

* Patients were initiated on sofosbuvir or ledipasvir-sofosbuvir between January 2014 and January 2017.

Table 2. Drugs taken while on treatment for sofosbuvir and ledipasvir-sofosbuvir*.

| Variable                        | Sofosbuvir | Ledipasvir-sofosbuvir |
|---------------------------------|------------|-----------------------|
|                                 | n = 1131   | n = 3331              |
| Average number of drugs per day, $^b$ mean | 4.46       | 3.05                  |
| Interferon and ribavirin use, n (%) |           |                       |
| Interferon                      | 169 (14.9) | 4 (0.1)               |
| Ribavirin                       | 937 (82.8) | 66 (2)                |
| Interferon and ribavirin$^c$     | 169 (14.9) | 3 (0.1)               |

* Patients were initiated on sofosbuvir or ledipasvir-sofosbuvir between January 2014 and January 2017.

* Any other drug, excluding sofosbuvir or ledipasvir-sofosbuvir.

* Counts for patients who took interferon and ribavirin were also counted in the separate counts for interferon and ribavirin.

https://doi.org/10.1371/journal.pone.0247843.t002
Discussion

Overview of findings

Over the past few years, the price of specialty drugs and their impact on public sector drug budgets has increased substantially [2]. We found that while the introduction of PharmaCare coverage for SOF and LDV/SOF increased treatment uptake substantially in the short-term, it did not appear to impact adherence rates to these drugs. At the same time, PharmaCare coverage rose and crowded out some of the private expenditure for SOF and LDV/SOF. Taken together, this suggests that public drug plans should prepare for significant increases in use after covering similar medications, but should not be concerned about lower adherence rates in the populations they serve.

Since prior studies have shown that decreased out-of-pocket costs were associated with higher adherence in other drugs [10, 11], one might expect that the availability of PharmaCare coverage would increase adherence rates. However, the lack of an effect of PharmaCare coverage on adherence found in this study may be due to the result of high pre-existing adherence levels. Two factors were likely at play in this result. First, adherence rates for SOF and LDV/
SOF were already high prior to the PharmaCare policy change. This may reflect the short duration of treatment and the severity of leaving HCV untreated. However, the overall high adherence rates across the pre- and post-periods were favourable, demonstrating that patients appeared to be taking the drugs for the full duration. Second, the prices of these drugs were beyond the financial means of most residents to pay out-of-pocket prior to public coverage. There was a rapid surge in treatment uptake following public coverage followed by a decline in treatment uptake. This surge was likely because patients were waiting for the government to eventually cover the drugs. The overall downward trend of uptake after the PharmaCare policy change was expected, as there would have eventually been fewer people left to be treated that would meet the eligibility criteria. These trends aligned with Liao and Fischer’s findings for Medicaid, where they also demonstrated a large increase in uptake in the beginning, which eventually slowed or stabilized [4]. Similar initial surge in treatment uptake following public coverage and decline thereafter has also been observed in Australia [21, 22]. When
PharmaCare expands its program to cover individuals with lower severity of HCV [23], we would expect to see similar trends: a spike in treatment uptake when eligibility criteria become less strict, and an overall decrease in uptake over time as there are fewer diagnosed individuals who are already linked with care left in the treatment pool. Sustained treatment uptake will require increasing diagnosis rates.

The increase in public expenditure also aligned with Liao and Fischer’s findings for Medicaid [4]. Large public expenditure was also previously seen in Australia, for a government-funded program for DAAs. Although the Australian government had budgeted $1 billion AUD over 5 years for DAAs, the expenditures in the first 18 months of the program approximated to $3.6 billion AUD; however, the exact direct expenditures are unknown due to a lack of transparency of rebates from manufacturers [24].

Limitations
Although ITS analysis is one of the most robust quasi-experimental designs, there are some limitations to our study worth noting. First, the PharmaNet data did not allow us to stratify private payments into insurance and out-of-pocket amounts. Therefore, the numbers we reported in this study included individual out-of-pocket payments (either paying for the treatment entirely on their own or co-payment) and the amount covered by private insurance. Second, we do not have a source of data on the criteria for coverage in the many private plans in BC. Thus, it was not possible to determine if differences in criteria drove any of the results.

Conclusions
Overall, PharmaCare coverage increased public expenditure and resulted in more individuals being able to access treatment. Reassuringly, the effect of public coverage on adherence was not significant when examined over time, and high adherence rates were maintained throughout our study period. This is a promising result, as it suggests public coverage does not result in an increase in poorer adherence to these expensive medicines. With the expansion of coverage in BC and coverage expansions in other jurisdictions, public payers should expect a significant increase in treatment uptake and public costs over the short term and plan resources accordingly.

Acknowledgments
We acknowledge the assistance of BCCDC, PHSA Performance Measurement and Reporting, Information Analysts, Ministry of Health Data Access, Research and Stewardship, MSP, DAD, Medical Beneficiary and Pharmaceutical Services program areas, BC Ministry of Health, BC Cancer Agency and their staff involved in data access, procurement and data management.

All inferences, opinions, and conclusions drawn in this manuscript are those of the authors, and do not reflect the opinions or policies of the Data Steward(s).

We would also like to acknowledge the assistance of Maria Alvarez, Stanley Wong, and Amanda Yu from The BC Hepatitis Testers Cohort Team, who are all affiliated with the BC Centre for Disease Control. Naveed Janjua is the lead and primary contact for this group (naveed.janjua@bccdc.ca).

Author Contributions
Conceptualization: Harriet Ho, Naveed Z. Janjua, Kimberlyn M. McGrail, Mark Harrison, Michael R. Law.

Data curation: Harriet Ho.
Formal analysis: Harriet Ho, Naveed Z. Janjua, Michael R. Law.

Funding acquisition: Michael R. Law.

Investigation: Harriet Ho, Naveed Z. Janjua, Michael R. Law.

Methodology: Harriet Ho, Naveed Z. Janjua, Kimberlyn M. McGrail, Mark Harrison, Michael R. Law.

Project administration: Naveed Z. Janjua, Michael R. Law.

Resources: Naveed Z. Janjua, Michael R. Law.

Supervision: Naveed Z. Janjua, Michael R. Law.

Validation: Harriet Ho, Naveed Z. Janjua, Kimberlyn M. McGrail, Mark Harrison.

Visualization: Harriet Ho, Michael R. Law.

Writing – original draft: Harriet Ho.

Writing – review & editing: Harriet Ho, Naveed Z. Janjua, Kimberlyn M. McGrail, Mark Harrison, Michael R. Law.

References

1. Gleason PP, Alexander CA, Starner CI, Ritter ST, Van Houten HK, Gunderson BW, et al. Health Plan Utilization and Costs of Specialty Drugs Within 4 Chronic Conditions. J Manag Care Pharm. 2013; 19(7):542–8. https://doi.org/10.18553/jmcp.2013.19.7.542 PMID: 23964615

2. Health Policy Brief: Specialty Pharmaceuticals. Health Aff. 2013;

3. Marshall AD, Saeed S, Barrett L, Cooper CL, Treloar C, Bruneau J, et al. Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study. C Open. 2016; 4(4):E605–14. https://doi.org/10.9778/cmaoj.20160008 PMID: 28018873

4. Liao JM, Fischer MA. Early Patterns of Sofosbuvir Utilization by State Medicaid Programs. N Engl J Med. 2015; 373(13):1280–1. https://doi.org/10.1056/NEJMct1506108 PMID: 26398092

5. Petersen T, Townsend K, Gordon LA, Siddharthan S, Silk R, Nelson A, et al. High adherence to all-oral directly acting antiviral HCV therapy in an inner-city patient population in a phase 2a study. Hepatol Int. 2015; 10(2):310–9. https://doi.org/10.1111/hij.12268 PMID: 26612014

6. Kamble P, Walker DR, Marx S, Harvey R, Uribe C, Bunniran S, et al. Adherence and discontinuation rates of sofosbuvir-based regimens: modeling real-world experience in a large managed care organization. 2015.

7. Butt AA, Yan P, Shaikh OS, Chung RT, Sherman KE. Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvir-based regimens: results from ERC-HIVES. Liver Int. 2016; 36(9):1275–83. https://doi.org/10.1111/liv.13103 PMID: 26928927

8. Louie V, Latt NL, Ghanibian D, Sahota A, Yanny BT, Mittal R, et al. Real-World Experiences With a Direct-Acting Antiviral Agent for Patients With Hepatitis C Virus Infection. Perm J. 2017; 21:1–6. https://doi.org/10.7812/TPP/16-096 PMID: 28368787

9. Trombatt WD, Koerner PH, Craft ZN, Miller RT, Kamal KM. Retrospective Analysis of the Medication Utilization and Clinical Outcomes of Patients Treated with Various Regimens for Hepatitis C Virus Infection. J Pharm Pract. 2017; 30(2):154–61. https://doi.org/10.1177/0897190015626008 PMID: 26763339

10. Choudhry NK, Fischer MA, Avorn J, Schneeweiss S, Solomon DH, Berman C, et al. At Pitney Bowes, Value-Based Insurance Design Cut Copayments And Increased Drug Adherence. Health Aff. 2010; 29(11):1995–2001. https://doi.org/10.1377/hlthaff.2010.0336 PMID: 21041738

11. Viswanathan M, Golin CE, Jones CD, Ashok M, Blalock SJ, Wines RC, et al. Interventions to Improve Adherence to Self-administered Medications for Chronic Diseases in the United States: A Systematic Review. Ann Intern Med. 2012; 157(11):785–95. https://doi.org/10.7326/0003-4819-157-11-201212040-00538 PMID: 22964778

12. Ministry of Health. B.C covers two curative hepatitis C drugs [Internet]. 2015 [cited 2015 Nov 16]. Available from: http://www2.news.gov.bc.ca/news_releases_2013-2017/2015HLTH0014-000386.htm
13. Daw J, Morgan SG. Stitching the gaps in the Canadian public drug coverage patchwork? A review of provincial pharmacare policy changes from 2000 to 2010. Health Policy (New York). 2012; 104(1):19–26. https://doi.org/10.1016/j.healthpol.2011.08.015 PMID: 21978939

14. Ministry of Health. PharmaCare for B.C. Residents [Internet]. [cited 2016 Apr 20]. Available from: http://www2.gov.bc.ca/gov/content/health/health-drug-coverage/pharmacare-for-bc-residents

15. Janjua NZ, Kuo M, Chong M, Yu A, Alvarez M. Assessing Hepatitis C Burden and Treatment Effectiveness through the British Columbia Hepatitis Testers Cohort (BC-HTC): Design and Characteristics of Linked and Unlinked Participants. PLoS One. 2016; 11(3):1–19. https://doi.org/10.1371/journal.pone.0150176 PMID: 26954020

16. Government of British Columbia. PharmaNet [Internet]. [cited 2016 Feb 8]. Available from: http://www2.gov.bc.ca/gov/content/health/health-drug-coverage/pharmacare-for-bc-residents/pharmanet

17. Population Data BC. PharmaNet [Internet]. 2015 [cited 2016 Feb 8]. Available from: https://www.popdata.bc.ca/data/external/PharmaNet

18. Jandoc R, Burden AM, Mamdani M, Levesque LE, Cadarette SM. Interrupted time series analysis in drug utilization research is increasing: systematic review and recommendations. J Clin Epidemiol. 2015; 68(8):950–6. https://doi.org/10.1016/j.jclinepi.2014.12.018 PMID: 25890805

19. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, et al. Global Distribution and Prevalence of Hepatitis C Virus Genotypes. Hepatology. 2014; 61(1):77–87. https://doi.org/10.1002/hep.27259 PMID: 25069599

20. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002; 27:299–309. https://doi.org/10.1046/j.1365-2710.2002.00430.x PMID: 12174032

21. Hajarizadeh B, Grebely J, Matthews G V, Martinello M, Dore GJ. Uptake of direct-acting antiviral treatment for chronic hepatitis C in Australia. J Viral Hepat. 2018; 00:1–9. https://doi.org/10.1111/jvh.12852 PMID: 29274192

22. The Kirby Institute U. Monitoring hepatitis C treatment uptake in Australia. 2017.

23. Ministry of Health. Chronic hepatitis C medication now available for all British Columbians. 2018.

24. Graaf B de, Yee KC, Clarke P, Palmer A. Uptake of and Expenditure on Direct-Acting Antiviral Agents for Hepatitis C Treatment in Australia. Appl Health Econ Health Policy. 2018; 108.